Sun Pharma Advanced Research (SPARC) Stock Soars After US Court Ruling on Sezaby PRV – What the 30% Two‑Day Rally on 3 December 2025 Really Means
SPARC shares surged nearly 30% in two days after a US court restored a Priority Review Voucher for its neonatal seizure drug Sezaby. The stock hit ₹179.5 on 3 December 2025, with trading volume topping 70 million shares, far above average. Despite the rally, SPARC’s 12-month price remains down about 38%. The US government has 60 days to appeal the court’s decision.
